• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Inspire agrees to sell InSite anti-infective

Article

Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).

Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).

The product combines a topical 1% azithromycin formulation with InSite's patented ophthalmic drug-delivery system (DuraSite), designed to increase ocular retention of the drug.

Under the agreement, InSite will grant Inspire exclusive rights to market the anti-infective in the United States and Canada. Inspire will make an initial $13 million payment to InSite, with an additional $19 million pending FDA grants regulatory approval. Inspire also will pay a 20% royalty on net sales for the first 2 years and 25% thereafter.

Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.